- Home
- Publications
- Publication Search
- Publication Details
Title
Personalized treatment in localized pancreatic cancer
Authors
Keywords
-
Journal
European Surgery-Acta Chirurgica Austriaca
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-10-02
DOI
10.1007/s10353-023-00814-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The NEONAX study
- (2023) Markus W. Büchler et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).
- (2023) Knut Jørgen Labori et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant therapy for pancreatic cancer
- (2023) Christoph Springfeld et al. Nature Reviews Clinical Oncology
- Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer
- (2023) Christoph Springfeld et al. JOURNAL OF CLINICAL ONCOLOGY
- Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
- (2023) Xu Zhou et al. Nature Cancer
- Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
- (2022) Eva Versteijne et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis
- (2022) Yuki Homma et al. Journal of Hepato-Biliary-Pancreatic Sciences
- The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain
- (2022) Christoph Springfeld et al. Nature Reviews Clinical Oncology
- Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01)
- (2022) Junpei Yamaguchi et al. ANNALS OF SURGERY
- Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer
- (2022) Thomas Hank et al. ANNALS OF SURGERY
- Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: A multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
- (2022) Lilian Schwarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.
- (2022) Rainer Fietkau et al. JOURNAL OF CLINICAL ONCOLOGY
- Ordered and deterministic cancer genome evolution after p53 loss
- (2022) Timour Baslan et al. NATURE
- Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas
- (2022) Matthew H. G. Katz et al. JAMA Oncology
- 1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)
- (2022) M.P. Ducreux et al. ANNALS OF ONCOLOGY
- Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) - a randomized phase II trial of the AIO pancreatic cancer group
- (2022) T. Seufferlein et al. ANNALS OF ONCOLOGY
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2022) Thierry Conroy et al. JAMA Oncology
- Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy
- (2022) Toshitaka Sugawara et al. JAMA Oncology
- Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial
- (2022) Paula Ghaneh et al. Lancet Gastroenterology & Hepatology
- Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
- (2021) Davendra P. S. Sohal et al. JAMA Oncology
- Adjuvant Chemotherapy After Neoadjuvant Chemotherapy for Pancreatic Cancer is Associated with Improved Survival for Patients with Low-Risk Pathology
- (2021) Elizabeth J. Olecki et al. ANNALS OF SURGICAL ONCOLOGY
- Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study
- (2021) Baobao Cai et al. LANGENBECKS ARCHIVES OF SURGERY
- LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival
- (2021) M. Tempero et al. ANNALS OF ONCOLOGY
- The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes
- (2021) Rosa Klotz et al. HPB
- Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
- (2021) Heidie Frisco Cabanos et al. Cancers
- Spatially confined sub-tumor microenvironments in pancreatic cancer
- (2021) Barbara T. Grünwald et al. CELL
- A Review of Pancreatic Cancer
- (2021) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Impact of Molecular Subtyping of Pancreatic Cancer
- (2021) Zhou Xu et al. Frontiers in Cell and Developmental Biology
- Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head
- (2020) Ross A. Abrams et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
- (2020) Eva Versteijne et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
- (2020) Michelle Chan-Seng-Yue et al. NATURE GENETICS
- Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
- (2020) Philip A Philip et al. Lancet Gastroenterology & Hepatology
- GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
- (2020) Grainne M. O'Kane et al. CLINICAL CANCER RESEARCH
- Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society
- (2020) Takuji Okusaka et al. PANCREAS
- A Phase I/II Study of Veliparib (ABT-888) in combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer
- (2020) Michael J Pishvaian et al. CLINICAL CANCER RESEARCH
- CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer – Final results
- (2020) M. Sinn et al. EUROPEAN JOURNAL OF CANCER
- Periarterial divestment in pancreatic cancer surgery
- (2020) Markus K. Diener et al. SURGERY
- Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: Surgical planning with the “halo sign” and “string sign”
- (2020) Joseph R. Habib et al. SURGERY
- Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment
- (2020) Stijn van Roessel et al. JAMA Oncology
- A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
- (2020) R. Nicolle et al. ANNALS OF ONCOLOGY
- Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
- (2020) Volker Kunzmann et al. Lancet Gastroenterology & Hepatology
- Chemotherapy for pancreatic cancer
- (2019) Christoph Springfeld et al. PRESSE MEDICALE
- Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05).
- (2019) Michiaki Unno et al. JOURNAL OF CLINICAL ONCOLOGY
- Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
- (2019) Mark J. Truty et al. ANNALS OF SURGERY
- APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
- (2019) Margaret A. Tempero et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival
- (2019) Ulrike Heger et al. HPB
- Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma
- (2019) Robert P. Jones et al. JAMA Surgery
- Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer
- (2019) Naim U. Rashid et al. CLINICAL CANCER RESEARCH
- Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma
- (2019) J. Medrano et al. PANCREATOLOGY
- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer
- (2018) Jin-Young Jang et al. ANNALS OF SURGERY
- Therapeutic developments in pancreatic cancer: current and future perspectives
- (2018) John P. Neoptolemos et al. Nature Reviews Gastroenterology & Hepatology
- International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017
- (2018) Shuji Isaji et al. PANCREATOLOGY
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It
- (2018) Sjors Klompmaker et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Optimizing the outcomes of pancreatic cancer surgery
- (2018) Oliver Strobel et al. Nature Reviews Clinical Oncology
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis
- (2017) Ali A. Mokdad et al. JOURNAL OF CLINICAL ONCOLOGY
- CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- (2017) Marianne Sinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
- (2016) Pascal Hammel et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
- (2016) Katsuhiko Uesaka et al. LANCET
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis
- (2016) Michael Tachezy et al. SURGERY
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer
- (2016) Matthew H. G. Katz et al. JAMA Surgery
- Pancreatic cancer
- (2016) Jorg Kleeff et al. Nature Reviews Disease Primers
- Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
- (2015) Cristina R. Ferrone et al. ANNALS OF SURGERY
- Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets
- (2015) Riccardo Casadei et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
- (2015) Richard A Moffitt et al. NATURE GENETICS
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
- (2014) Henriette Golcher et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
- (2012) Werner Hartwig et al. ANNALS OF SURGICAL ONCOLOGY
- What We Have Learned About Pancreatic Cancer From Mouse Models
- (2012) Pedro A. Pérez–Mancera et al. GASTROENTEROLOGY
- Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia
- (2012) Mitsuro Kanda et al. GASTROENTEROLOGY
- Open-Label, Multicenter, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon Alfa-2b Versus Fluorouracil and Folinic Acid for Patients With Resected Pancreatic Adenocarcinoma
- (2012) Jan Schmidt et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial
- (2011) William F. Regine et al. ANNALS OF SURGICAL ONCOLOGY
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
- (2011) Eric A Collisson et al. NATURE MEDICINE
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
- (2009) Mark P. Callery et al. ANNALS OF SURGICAL ONCOLOGY
- A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
- (2009) H Ueno et al. BRITISH JOURNAL OF CANCER
- Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma
- (2008) William F. Regine et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
- (2008) Matthew H.G. Katz et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now